INVO Fertility reported a 23% increase in revenue driven by strong organic growth in its clinics and expansion of its INVOcell technology. Despite revenue growth, the company experienced a widening net loss and a slight deterioration in Adjusted EBITDA, indicating ongoing challenges in achieving profitability.
Total revenue increased 23% year-over-year to $1.76 million.
positiveConsolidated clinic revenue grew 21% year-over-year to $1.72 million.
positiveRevenue from all clinics (including equity method) increased 18% year-over-year to $2.00 million.
positiveINVOcell device revenue experienced 130% year-over-year growth.
positiveThe company is pursuing an active acquisition strategy with a growing pipeline of target clinics.
neutralRecent U.S. policy updates enable employers to offer standalone infertility benefits, creating a significant market opportunity.
neutralNet loss widened to $(2.6) million in Q3 2025 from $(1.6) million in Q3 2024.
negativeAdjusted EBITDA was $(947,568) in Q3 2025, a slight deterioration from $(945,949) in Q3 2024.
attentionTotal operating expenses increased significantly to $3.39 million in Q3 2025 from $2.73 million in Q3 2024, outpacing revenue growth.
negativeSelling, general and administrative expenses increased by 40.5% year-over-year to $2.13 million.
negativeBasic and diluted net loss per share was $(0.77) in Q3 2025, compared to $(15.11) in Q3 2024, though the prior year's figure was heavily impacted by discontinued operations.
attentionWeighted average diluted shares outstanding increased significantly to 3,447,622 in Q3 2025 from 107,949 in Q3 2024, indicating dilution from new share issuances.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Clinic Revenue | N/A | — | — | — |
Product Revenue | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Meaningful progress across two core pillars: strengthening organic performance and advancing acquisition opportunities.
Robust 18% organic growth across clinics driven by higher patient volume and increased awareness.
Policy momentum with federal updates enabling standalone infertility benefits is a significant opportunity.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.